

## United States Patent and Trademark Office

 $\mathcal{U}$ 

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	Fi	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/619,739	C	07/14/2003	Frederick C. Christians	3502.1	7040	
22886	7590	06/14/2006		EXAM	EXAMINER	
AFFYMETRIX, INC				KAPUSHOC, STEPHEN THOMAS		
ATTN: CHIE	EF IP COU	JNSEL, LEGAL DE	PT.			
3420 CENTRAL EXPRESSWAY				ART UNIT	PAPER NUMBER	
SANTA CLARA, CA 95051				1634	-	

DATE MAILED: 06/14/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)					
	Office Action Summan	10/619,739	CHRISTIANS, FREDERICK C.					
	Office Action Summary	Examiner	Art Unit					
		Stephen Kapushoc	1634					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply								
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPL CHEVER IS LONGER, FROM THE MAILING D nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. In period for reply is specified above, the maximum statutory period the to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be time will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).					
Status								
1) 又	Responsive to communication(s) filed on <u>03 A</u>	pril 2006.						
	This action is <b>FINAL</b> . 2b) ☐ This action is non-final.							
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims							
4)🛛	4)⊠ Claim(s) <u>1-30</u> is/are pending in the application.							
	4a) Of the above claim(s) is/are withdrawn from consideration.							
5)[	5) Claim(s) is/are allowed.							
6)[	6) Claim(s) is/are rejected.							
7)	) Claim(s) is/are objected to.							
8)⊠	8) Claim(s) <u>1-30</u> are subject to restriction and/or election requirement.							
Applicati	on Papers							
9)[	The specification is objected to by the Examine	er.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).								
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.								
Priority u	ınder 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) All b) Some * c) None of:								
<ol> <li>Certified copies of the priority documents have been received.</li> </ol>								
2. Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in this National Stage								
application from the International Bureau (PCT Rule 17.2(a)).								
* See the attached detailed Office action for a list of the certified copies not received.								
Attachmen	tle)							
_	e of References Cited (PTO-892)	4) Interview Summary	(PTO-413)					
2) D Notic	e of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate					
	nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) r No(s)/Mail Date	5) Notice of Informal P 6) Other:	Patent Application (PTO-152)					

## **DETAILED ACTION**

The examiner handling this application has changed and is now Stephen Kapushoc in Art Unit 1634. Please address future correspondence concerning this application to the above named examiner.

The previous Requirement for Restriction of 03/03/2006 is vacated and a new requirement is set forth as follows:

## Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-21 and 28-30, drawn to DNA molecules with at least one Tag gene, classified in class 536, subclass 23.5.
  - II. Claims 22-27, drawn to a method for analyzing gene expression comprising providing a control for an array assay, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

2. Invention I is related as product and process of use with invention II. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product. See MPEP § 806.05(h). In the instant case the

Application/Control Number: 10/619,739 Page 3

Art Unit: 1634

polynucleotides of the invention of Group I can be used in processes other than those of Group II, such as for synthesizing polypeptides or for therapeutic processes.

## **Requirement for Further Restriction:**

3. Additionally, each group named above is subject to a further restriction.

Applicant is required to further select: (i) a specific combination of Tag sequences from those enumerated in SEQ ID NOS: 1-2050; and (ii) a specific Tag gene from those enumerated in SEQ ID NOS: 2051-2066. The Tag sequences selected in (i) shall be the Tag sequences that comprise the Tag gene selected in (ii).

This is NOT an election of species. Claims that specifically recite particular Tag sequences or Tag genes will only be examined insofar as they require the selected elements.

The different polynucleotides are unique sequences that are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions within the meaning of 35 U.S.C 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141. By statute, "[i]f two or more independent and distinct inventions are claimed in one application, the Commissioner may require the application to be restricted to one of the inventions." 35 U.S.C. 121. Pursuant to this statute, the rules provide that "[i]f two or more independent and distinct inventions are claimed in a single application, the examiner in his action shall require the applicant... to elect that invention to which his claims shall be restricted." 37 CFR 1.142 (a). See also 37 CFR 1.141(a).

Application/Control Number: 10/619,739

Art Unit: 1634

4. Regarding the Requirement for Further Restriction, the search and examination of all possible groups and all possible sequences would pose an enormous burden on the examiner and on the PTO search resources. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as demonstrated by their different classification and recognized divergent subject matter due to all of the inventions' different gene sequences would require different searches that are not coextensive, examination of these claims would pose a serious burden on the examiner and therefore the restriction is deemed proper.

Page 4

5. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised

Application/Control Number: 10/619,739 Page 5

Art Unit: 1634

that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder.

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

6. A telephone call was made to Thomas Malone on 5/11/2006 to request an oral election to the above restriction requirement, but did not result in an election being made.

7. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stephen Kapushoc whose telephone number is 571-272-3312. The examiner can normally be reached on Monday through Friday, from 8am until 5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached at 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Stephen Kapushoc Art Unit 1634

JULIET C. SWITZER
PRIMARY EXAMINER